NetworkNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) F
Post# of 111
(Total Views: 194)
Posted On: 08/02/2022 4:48:41 PM
NetworkNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Featured in Bell2Bell Podcast
Aditxt (NASDAQ: ADTX) was featured in the Bell2Bell Podcast, a part of IBN’s (InvestorBrandNetwork) sustained effort to provide specialized content distribution via widespread syndication channels. Amro Albanna, co-founder, chairman and CEO of Aditxt, joined the latest episode to provide an overview of the company and discuss its business model. “We are a biotech innovation company, and our focus is on immune diseases. The reality is that immune diseases are caused either by someone having too little immune response or too much immune response,” Albanna said. “When you have too little immune response and you’re dealing with COVID-19, we all understand the story, and that applies to other viral diseases. Too much immunity is also not a good thing. When you have too much immune response, you get into the area of autoimmune diseases – multiple sclerosis, type I diabetes and psoriasis. These all happen when our immune system begins to overreact and attack our own tissues and cells.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Aditxt (NASDAQ: ADTX) was featured in the Bell2Bell Podcast, a part of IBN’s (InvestorBrandNetwork) sustained effort to provide specialized content distribution via widespread syndication channels. Amro Albanna, co-founder, chairman and CEO of Aditxt, joined the latest episode to provide an overview of the company and discuss its business model. “We are a biotech innovation company, and our focus is on immune diseases. The reality is that immune diseases are caused either by someone having too little immune response or too much immune response,” Albanna said. “When you have too little immune response and you’re dealing with COVID-19, we all understand the story, and that applies to other viral diseases. Too much immunity is also not a good thing. When you have too much immune response, you get into the area of autoimmune diseases – multiple sclerosis, type I diabetes and psoriasis. These all happen when our immune system begins to overreact and attack our own tissues and cells.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)ADiTx Therapeutics Inc. (ADTX) Stock Research Links
Scroll down for more posts ▼